Humacyte Inc

NASDAQ:HUMAUnited States

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Contact Information

Headquarters

2525 East North Carolina Highway 54DURHAM, NC, United States 27713

Phone

919-313-9633

Fax

302-655-5049

Executives

Independent Chairman of the Board

Kathleen Sebelius

President, Chief Executive Officer, Director

Laura Niklason

Chief Financial Officer, Chief Corporate Development Officer, Treasurer

Dale Sander

Chief Operating Officer

Heather Prichard

Chief Regulatory Officer

Yang Cao